TX-MARY-KAY-ASH-FOUNDTN
10.11.2021 14:45:07 CET | Business Wire | Press release
In celebration of its 25th anniversary and guided by Mary Kay Ash’s dream to enrich the lives of women worldwide, the Mary Kay Ash FoundationSM released its first-ever Foundation Annual Report, as well as a new name, logo website and rebranding. Since 1996, the Foundation has contributed more than $80 million to organizations aligned with its two-fold mission: funding research for cancers affecting women and ending domestic violence and gender-based violence against women and girls.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005237/en/
For more than two decades, the Foundation has continued to innovate as a global charitable leader focused on women. To commemorate its milestone anniversary, the organization made a slight name change from The Mary Kay FoundationSM to Mary Kay Ash FoundationSM to improve search engine optimization. In addition, the Foundation unveiled a new logo and website, rebranding and the first-ever Mary Kay Ash FoundationSM Annual Report . The report gives an overview of the 2020 initiatives in the United States and around the world. Key findings in the report include:
- In 2020, the Mary Kay Ash FoundationSM awarded grants totaling $1,825,000 to causes in the U.S. and those that will make a difference throughout the world via the Innovative/Translational Cancer Research Grants and the International Post-Doctoral Fellowship Cancer Research Program . Since 1996, the Mary Kay Ash FoundationSM has supported innovative cancer research and clinical trials to find a cure for cancers affecting women by awarding more than $25 million for over 250 cutting-edge projects at leading medical schools and research institutions worldwide.
- Due to the COVID-19 pandemic, a devastating increase was reported in domestic violence across the world in 2020. This pandemic within a pandemic stretched domestic violence shelters to their limits. The Mary Kay Ash FoundationSM awarded emergency grants totaling $1,000,000 to support domestic violence frontline workers – the first responders for women and children. In an effort to expand a global commitment to eradicate gender-based domestic violence, Mary Kay Inc. and the Mary Kay Ash FoundationSM joined forces with the United Nations Trust Fund to End Violence Against Women and CARE USA , humanitarian global leaders. Since 2000, the Foundation has donated more than $58 million to ending gender-based violence. The effort has supported over six million women and girls seeking shelter and services from abuse.
“Twenty-five years ago, my grandmother, Mary Kay Ash, created the Foundation that continues to remain at the heart of Mary Kay Inc., company employees and independent beauty consultants who strive to uphold her vision of making the world a better place for women and their families,” said Ryan Rogers, Chief Investment Officer and Vice President of the Mary Kay Ash FoundationSM Board of Directors. “While the Mary Kay Ash FoundationSM planted its roots in Texas and watched them spread across the United States, much like the company itself, the work of the Foundation knows no borders. We envision a world where women are empowered, healthy and safe. On this milestone anniversary, we continue our steadfast commitment to women worldwide and are reminded of how truly honored we are to continue doing my grandmother’s work.”
For more information, visit marykayashfoundation.org .
About the Mary Kay Ash FoundationSM
Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash FoundationSM raises and distributes funds to invest in breakthrough cancer research to find a cure for women-related cancers and ending domestic violence against women. Since 1996, the Mary Kay Ash FoundationSM has contributed more than $80 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Together, we can make the world better for women. To learn more about how to educate, advocate, volunteer and donate, and join life-saving work to support and empower women, visit marykayashfoundation.org , find us on Facebook and Instagram , or follow us on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
